From: New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway
 | CMM | SCC | ||||||
---|---|---|---|---|---|---|---|---|
 | Women | % | Men | % | Women | % | Men | % |
Age at 1 st diagnosis | Â | Â | Â | Â | Â | Â | Â | Â |
20-40 | 3249 | 21.5 | 1943 | 15.0 | 248 | 2.3 | 270 | 2.0 |
40-59 | 5435 | 35.9 | 4908 | 38.0 | 1201 | 11.0 | 1492 | 10.9 |
≥ 60 | 6452 | 42.6 | 6082 | 47.0 | 9474 | 86.7 | 11 935 | 87.1 |
Age (median) | 55.6 | Â | 57.4 | Â | 75.4 | Â | 73.2 | Â |
Anatomical site | Â | Â | Â | Â | Â | Â | Â | Â |
Head/neck | 2148 | 14.2 | 2025 | 15.7 | 6560 | 60.0 | 8809 | 64.3 |
Trunk | 4353 | 28.8 | 7044 | 54.4 | 1659 | 15.2 | 2071 | 15.1 |
Arm | 2346 | 15.5 | 1188 | 9.2 | 1103 | 10.1 | 1281 | 9.4 |
Leg/foot | 5633 | 37.2 | 1786 | 13.8 | 1060 | 9.7 | 737 | 5.4 |
Other sites | 656 | 4.3 | 890 | 6.9 | 541 | 5.0 | 799 | 5.8 |
Residential region | Â | Â | Â | Â | Â | Â | Â | Â |
South | 10 875 | 71.9 | 9270 | 71.7 | 7878 | 72.1 | 9537 | 69.6 |
Mid | 2998 | 19.8 | 2525 | 19.5 | 2235 | 20.5 | 2877 | 21.0 |
North | 1263 | 8.3 | 1138 | 8.8 | 810 | 7.4 | 1283 | 9.4 |
Educational level | Â | Â | Â | Â | Â | Â | Â | Â |
≤ Primary school | 496 | 3.3 | 617 | 4.8 | 420 | 3.8 | 653 | 4.8 |
Secondary school | 5199 | 34.4 | 3446 | 26.6 | 5678 | 52.0 | 5847 | 42.7 |
Some college | 4545 | 30.0 | 3271 | 25.3 | 3106 | 28.4 | 3359 | 24.5 |
≥ College degree | 4896 | 32.3 | 5599 | 43.3 | 1719 | 15.8 | 3830 | 28.0 |
Marital status | Â | Â | Â | Â | Â | Â | Â | Â |
Not married | 6270 | 41.4 | 3515 | 27.2 | 6981 | 63.9 | 4641 | 33.9 |
Married | 8866 | 58.6 | 9418 | 72.8 | 3942 | 36.1 | 9056 | 66.1 |
Parental status | Â | Â | Â | Â | Â | Â | Â | Â |
No children | 3875 | 25.6 | 2989 | 23.1 | 3855 | 35.3 | 4226 | 30.9 |
Children | 11 261 | 74.4 | 9944 | 76.9 | 7068 | 64.7 | 9471 | 69.1 |
Annual income | Â | Â | Â | Â | Â | Â | Â | Â |
No or missing | 6467 | 42.7 | 4118 | 31.8 | 8930 | 81.7 | 9523 | 69.5 |
$ 1-9999 | 2573 | 17.0 | 1639 | 12.7 | 801 | 7.3 | 1609 | 11.8 |
$ 10 000–19 999 | 1712 | 11.3 | 1283 | 9.9 | 320 | 3.0 | 567 | 4.1 |
$ 20 000–39 999 | 2326 | 15.4 | 2166 | 16.8 | 462 | 4.2 | 782 | 5.7 |
$ ≥ 40 000 | 2058 | 13.6 | 3727 | 28.8 | 410 | 3.8 | 1216 | 8.9 |
Duration of follow-up (years) | Â | Â | Â | Â | Â | Â | Â | |
0.0-2.0 | 2551 | 16.9 | 3050 | 23.6 | 2642 | 24.2 | 3491 | 25.5 |
2.1-5.0 | 2938 | 19.4 | 3235 | 25.0 | 3019 | 27.6 | 3875 | 28.3 |
5.1-10.0 | 3044 | 20.1 | 2610 | 20.2 | 2658 | 24.3 | 3427 | 25.0 |
10.1-15.0 | 2261 | 14.9 | 1577 | 12.2 | 1398 | 12.8 | 1655 | 12.1 |
15.1-20.0 | 1720 | 11.4 | 1088 | 8.4 | 648 | 6.0 | 690 | 5.0 |
20.1-25.0 | 1109 | 7.3 | 615 | 4.8 | 289 | 2.6 | 313 | 2.3 |
≥ 25.1 | 1513 | 10.0 | 758 | 5.8 | 269 | 2.5 | 246 | 1.8 |
Total number | 15 136 | 100 | 12 933 | 100 | 10 923 | 100 | 13 697 | 100 |
No subsequent cancer | 13 078 | 86.4 | 10 995 | 85.0 | 9030 | 82.7 | 9978 | 72.9 |
Any subsequent cancer | 2058 | 13.6 | 1938 | 15.0 | 1893 | 17.3 | 3719 | 27.1 |